Business Description
IRIDEX Corp
NAICS : 334510
SIC : 3845
ISIN : US4626841013
Total Employee Number:
108Description
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.08 | |||||
Equity-to-Asset | 0.17 | |||||
Debt-to-Equity | 0.9 | |||||
Debt-to-EBITDA | -2.81 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.11 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -4.5 | |||||
3-Year EBITDA Growth Rate | 46.2 | |||||
3-Year EPS without NRI Growth Rate | 17.9 | |||||
3-Year FCF Growth Rate | 40 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.7 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.27 | |||||
9-Day RSI | 46.25 | |||||
14-Day RSI | 49.77 | |||||
3-1 Month Momentum % | 19.35 | |||||
12-1 Month Momentum % | 28.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.92 | |||||
Quick Ratio | 1.19 | |||||
Cash Ratio | 0.36 | |||||
Days Inventory | 93.42 | |||||
Days Sales Outstanding | 51.34 | |||||
Days Payable | 59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.7 | |||||
Shareholder Yield % | -1.93 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 35.97 | |||||
Operating Margin % | -5.12 | |||||
Net Margin % | -6.23 | |||||
EBITDA Margin % | -2.9 | |||||
FCF Margin % | -4.82 | |||||
OCF Margin % | -4.38 | |||||
ROE % | -77.07 | |||||
ROA % | -10.8 | |||||
ROIC % | -15.13 | |||||
3-Year ROIIC % | -80.86 | |||||
ROC (Joel Greenblatt) % | -41.3 | |||||
ROCE % | -15.91 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.37 | |||||
EV-to-EBIT | -9.42 | |||||
EV-to-EBITDA | -16.63 | |||||
EV-to-Revenue | 0.48 | |||||
EV-to-Forward-Revenue | 0.48 | |||||
EV-to-FCF | -10 | |||||
Price-to-GF-Value | 0.66 | |||||
Price-to-Median-PS-Value | 0.42 | |||||
Earnings Yield (Greenblatt) % | -10.62 | |||||
FCF Yield % | -12.88 | |||||
Forward Rate of Return (Yacktman) % | -0.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IRIX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IRIDEX Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 52.578 | ||
| EPS (TTM) ($) | -0.19 | ||
| Beta | -0.4818 | ||
| 3-Year Sharpe Ratio | -0.09 | ||
| 3-Year Sortino Ratio | -0.16 | ||
| Volatility % | 72.59 | ||
| 14-Day RSI | 49.77 | ||
| 14-Day ATR ($) | 0.041677 | ||
| 20-Day SMA ($) | 1.1475 | ||
| 12-1 Month Momentum % | 28.54 | ||
| 52-Week Range ($) | 0.8688 - 1.6481 | ||
| Shares Outstanding (Mil) | 17.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IRIDEX Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IRIDEX Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-11 17:00 | In 129 days | ||
| Third quarter earnings results for 2026 | 2026-11-11 | In 128 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 17:00 | In 38 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 37 days | ||
| Guidance call for 2026 | 2026-06-17 16:00 | 1.19 (+0.85%) | ||
| General meeting for 2026 | 2026-06-12 08:00 | 1.12 (-1.32%) | ||
| First quarter earnings conference call for 2026 | 2026-05-19 17:00 | 1.02 (+0.50%) | ||
| First quarter earnings results for 2026 | 2026-05-19 | 1.02 (+0.50%) | ||
| Annual report for 2025 | 2026-04-02 | 0.95 (-5.98%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-26 17:00 | 1.33 (-2.57%) |
Show
Entries
IRIDEX Corp Frequently Asked Questions
What is IRIDEX Corp(IRIX)'s stock price today?
The current price of IRIX is $1.13. The 52 week high of IRIX is $1.65 and 52 week low is $0.87.
When is next earnings date of IRIDEX Corp(IRIX)?
The next earnings date of IRIDEX Corp(IRIX) is 2026-08-12 Est..
Does IRIDEX Corp(IRIX) pay dividends? If so, how much?
IRIDEX Corp(IRIX) does not pay dividend.
Guru Commentaries on NAS:IRIX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on IRIDEX Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers